Vicentra BV has closed a $74 million series C financing round to accelerate the European rollout of its wearable insulin patch. The small, lightweight system Kaleido is the company’s flagship product and consists of two pumps controlled by a Bluetooth wireless connected handset. The small size rests on a pumping action that – unlike a conventional syringe mechanism – uses micro-pulse technology to deliver accurate and consistent doses of insulin.

V-Wave Ltd. said on Dec. 17 that it has closed all remaining tranches of a $98 million extended series C financing led by Deerfield Management. The funds will be used to complete a pivotal IDE  trial for its Ventura interatrial shunt system for the treatment of advanced heart failure (HF) and submit a PMA to the FDA for U.S. marketing approval.

LONDON – Metabolic diseases specialist Northsea Therapeutics BV closed a $80 million series C to fund phase II development in two further indications, as it awaits the final results from the phase IIb trial of its lead product, icosabutate, in the treatment of nonalcoholic steatohepatitis (NASH), which are due at the start of 2023.

PARIS – Dyameo SAS has successfully raised $1.13 million in seed funding to develop its endoscopy probe used for the instantaneous detection of cancerous cells. This round was led by  Medevice SAS and Aquiti Gestion SAS via its co-investment fund, NACO.